top of page

AstraZeneca’s Lynparza shows significant PFS benefit in ovarian cancer patients

A phase III trial designed to evaluate the efficacy of AstraZeneca’s Lynparza (olaparib) tablets as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer has demonstrated significant progression-free survival (PFS) benefit.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page